Jiangsu Hengrui Pharmaceuticals (SHA:600276) will conduct clinical trials on the SHR0302 alkaline gel as a treatment for vitiligo after obtaining the approval of Chinese drug regulator National Medical Products Administration, according to the company's filing on the Shanghai Stock Exchange.
About 855.3 million yuan has been invested into the research and development of SHR0302-related drugs, which were approved as treatment for ankylosing spondylitis, atopic dermatitis and rheumatoid arthritis, the pharmaceutical company said in its Wednesday filing.
Price (RMB): ¥42.89, Change: ¥-0.13, Percent Change: -0.30%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments